Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Qualigen Therapeutics Inc (QLGN)

Qualigen Therapeutics Inc (QLGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model Globe Newswire - Mon Aug 1, 2022

CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing...

QLGN : 0.3050 (+6.09%)
Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302 Globe Newswire - Wed Jul 6, 2022

CARLSBAD, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing...

QLGN : 0.3050 (+6.09%)
Qualigen Therapeutics to Present at BIO International Convention Globe Newswire - Tue Jun 14, 2022

CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing...

QLGN : 0.3050 (+6.09%)
Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials Globe Newswire - Tue Jun 7, 2022

A Potential Treatment for Pancreatic Cancer in Addition to Other Tumors of High Unmet Clinical Need CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE)...

QLGN : 0.3050 (+6.09%)
Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex Globe Newswire - Thu Jun 2, 2022

Transaction expected to significantly advance commercial readiness of NanoSynex’s innovative diagnostics technology platform focused on the $30+ Billion...

QLGN : 0.3050 (+6.09%)
Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting Globe Newswire - Thu May 26, 2022

Abstracts Highlight In Vitro and In Vivo Activity of Qualigen’s Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath...

QLGN : 0.3050 (+6.09%)
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference Globe Newswire - Fri May 20, 2022

CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing...

QLGN : 0.3050 (+6.09%)
Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results Globe Newswire - Fri May 13, 2022

CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing...

QLGN : 0.3050 (+6.09%)
Qualigen Therapeutics’ Partner NanoSynex to Present Technology at BioMed Israel Globe Newswire - Tue May 10, 2022

Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) --...

QLGN : 0.3050 (+6.09%)
Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex Globe Newswire - Tue May 3, 2022

Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “Superbugs,” a Rising Global Health Crisis CARLSBAD, Calif., May ...

QLGN : 0.3050 (+6.09%)

Barchart Exclusives

Is Palo Alto Stock a Buy Right Now? Barchart - Sat May 25, 11:45AM CDT
Cybersecurity stock Palo Alto got punished after lowering the upper rail of its billings guidance, but analysts say the sell-off was an overreaction. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot